Fig. 2
Venetoclax and Daratumumab combination inhibits AML disease progression in vivo. a Schematic of the in vivo model used for these experiments. b 0.5 × 106 MV411 cells or primary AML (#3) were injected into the tail vein of NSG mice. Mice were imaged using bioluminescence at day 7 following injection to confirm tumor engraftment, and then split into four groups. Group 1 received vehicle (PBS), group 2 received Daratumumab (Dara; 5 mg/kg) on day 7 and day 14 by intra-peritoneal (IP) injection, group 3 received Venetoclax (Ven; 100 mg/kg) daily by oral gavage (OG) and group 4 received Venetoclax (Ven; 100 mg/kg) daily by OG and Daratumumab (Dara; 5 mg/kg) on day 7 and day 14 by IP. Mice were then imaged using bioluminescence at day 17. c and d Densitometry of the bioluminescent images shown in (B) was performed to determine differences between vehicle, Daratumumab alone, Venetoclax alone or Daratumumab and Venetoclax treated animals. (n > 4). Statistical tests used was Kruskal-Wallis statistical test followed by Dunn’s multiple comparisons. Data shown are means ± SD *P < 0.05 **P < 0.01. (E and F) Kaplan-Meier survival curves of treatment groups